Triple‐negative and HER2‐amplified DCIS represent only 5% and 25% of all DCIS cases, respectively, and are believed to be the most aggressive subtypes, which is also reflected by the fact that both CDX models show rapid progression to invasive disease.14 This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.